Nuvectis Pharma (NVCT) Other financing activities (2021 - 2023)
Nuvectis Pharma (NVCT) posted Other financing activities of $14000.0 for Q3 2023, down 99.87% sequentially from $10.5 million in Q2 2023, and down 97.5% YoY from $559000.0 in Q3 2022.
Nuvectis Pharma (NVCT) Other financing activities (2021 - 2023) Analysis & Trends
Nuvectis Pharma has reported Other financing activities for 3 years, with the latest figure at $14000.0 in Q3 2023.
- Quarterly Other financing activities fell 97.5% year-over-year to $14000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $11.2 million (down 34.43% YoY) and the FY2023 annual result came in at $11.2 million, down 30.05% from the prior year.
- Other financing activities eased to $14000.0 in Q3 2023 per NVCT's latest filing, from $10.5 million in the prior quarter.
- Over five years, Other financing activities peaked at $16.0 million in Q1 2022 and troughed at $14000.0 in Q3 2023.
- A 3-year average of $3.7 million and a median of $630500.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 1954.12% in 2023, down 97.5% in 2023.
- Over 3 years, Other financing activities stood at $136000.0 in 2021, then surged by 311.03% to $559000.0 in 2022, then slumped by 97.5% to $14000.0 in 2023.
- According to Business Quant data, Other financing activities over the past three periods registered $14000.0, $10.5 million, and $702000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 14,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Jun 30, 2023 | 10.48 Mn |
| Jun 30, 2023 | 10.48 Mn |
| Mar 31, 2023 | 702,000.00 |
| Mar 31, 2023 | 702,000.00 |
| Sep 30, 2022 | 559,000.00 |
| Sep 30, 2022 | 559,000.00 |
| Jun 30, 2022 | 510,000.00 |
| Jun 30, 2022 | 510,000.00 |
| Mar 31, 2022 | 16.00 Mn |
| Mar 31, 2022 | 16.00 Mn |
| Sep 30, 2021 | 136,000.00 |
| Sep 30, 2021 | 136,000.00 |
| Jun 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 1.57 Mn |